Endocrine and associated consequences of conservative and chemo- and hormonal therapy in cancer treatment: opportunities and extent of the feasibility of correction.

Treatment of patients with malignant tumors, largely involves the use of chemotherapy, targeted therapy and endocrine therapy (anti-hormonal and hormonal drugs). Depending on the location and nature of the tumor, surgical interventions aiming to remove some endocrine organs (in particular, ovarian, testicular, thyroid and endocrine portion of the pancreas, etc.) can lead to disruption of their function. The objective of presented study is to focus our attention mainly on the effects (including the steroid and non-steroidal components) of anticancer treatment in the endocrine system and in the outcomes associated with hormonal and metabolic changes, clinical and phenotypic features. These effects are manifested not only by changes of laboratory and instrumental parameters, but also accompanied by changes in the clinical manifestations of the disease and the patient's subjective feelings. The therapy often has adverse effects, as the anticipated final results of influence of such processes as weight gain, dyslipidemia, impaired glucose tolerance, lack of ovarian, adrenal, growth hormone and testicular function, osteopenia, hot flushes, chronic fatigue e.t.c., which often limits the success of treatment. Passive registration of such violations, and the silent watching them – is only one side of the problem rather frequent enough, the other side - are the questions about modern approaches of their correction and its feasibility. In part, this problem has a genetic basis, which, along with other indicators, can determine not only the response to anti-tumor therapy, but the severity of endocrine changes, their potential prognostic role, as well as the indications for their prevention and elimination. There are many clinically significant situations that are need to be analysed and discussed, such as: complete androgen blockade in prostate cancer patients, endocrine effects of adjuvant chemotherapy and hormonal therapy in breast cancer patients of reproductive and postmenopausal age, the expected increase of the frequency of performing of preventive salpingoovariectomies in carriers of mutations in BRCA1 and BRCA2 genes, thyroid (in particular) and adrenocortical tropism of targeted therapy, consequences of high doses of corticosteroid support therapy, etc., that demonstrate the importance of this problem, considering these facts in clinical practice and the establishment of standards for the management of patients with these problems.

1. Берштейн Л. М. Онкоэндокринология: традиции, современность, перспективы. СПб: Наука. 2004, 344с.

2. Innovative Endocrinology of Cancer (eds. Lev M. Berstein, Richard J. Santen). Springer Science / Landes Bioscience. Austin, Texas (USA). 2008, 242p.

3. World Cancer Report (eds. Peter Boyle, Bernard Levin). International Agency for Research on Cancer. Lyon, 2008, 512p.

4. Amir E., Seruga B., Martinez-Lopez J. et al. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs // J Clin Oncol. — 2011. — Vol. 29 (18). — P.2543-2549.

5. Niraula S., Seruga B., Ocana A. et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs // J Clin Oncol. — 2012. — Vol. 30 (24). — P.3012-3019.

6. Vera-Badillo F. E., Al-Mubarak M., Templeton A. J., Amir E. Benefit and harms of new anti-cancer drugs // Curr Oncol Rep. — 2013. — Vol. 15 (3). — P.270-275.

7. Frechette D., Paquet L., Verma S. et al. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study // Breast Cancer Res. Treat. — 2013. — Vol. 141. — P.111-117.

8. Amir E., Seruga B., Niraula S. et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis // J Natl Cancer Inst. — 2011. — Vol. 103 (17). — P.1299-1309.

9. Johansson H, Gandini S, Guerrieri-Gonzaga A et al. Effect of fenretinide and low dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer //Cancer Res. 2008. — Vol. 68 (22). — P.9512-9518.

10. Иванов В. Г., Цырлина Е. В., Коваленко И. Г. и др. Связь гормонально-метаболического статуса больных раком молочной железы с эффективностью адъювантной гормонотерапии // Вопр. онкол. — 2006. — Т.52 (2). — С.150-154.

11. Goodwin PJ, Ennis M, Pritchard KI. et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study // J Clin Oncol. 2002. — Vol. 20 (1). P.42-51.

12. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis // Breast Cancer Res Treat. — 2010. — Vol.123 (3). — P.627-635.

13. Campbell KL, Lane K, Martin AD. et al. Resting energy expenditure and body mass changes in women during adjuvant chemotherapy for breast cancer // Cancer Nurs. 2007. — Vol. 30 (2). — P.95-100.

14. Tr dan O, Bajard A, Meunier A. et al. Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study // Clin Nutr. — 2010. — Vol.29 (2). — P.187-91.

15. Gordon AM, Hurwitz S, Shapiro CL, LeBoff MS. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer // Menopause. — 2011. — Vol. 18 (11). — P.1244-1248.

16. Su HI. Measuring ovarian function in young cancer survivors // Minerva Endocrinol. — 2010. — Vol. 35 (4). — P.259-270.

17. Torino F, Barnabei A, De Vecchis L. et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer // Crit Rev Oncol Hematol. — 2013 [Epub ahead of print].

18. Тюляндин С. А. Системная терапия операбельного рака молочной железы. Практическая онкология: избранные лекции (ред. Тюляндин С. А., Моисеенко В. М.). Спб: Центр ТОММ. 2004, c. 73-83.

19. Семиглазов В. Ф., Семиглазов В. В., Клетсель А. Е. Неоадъювантное и адъювантное лечение рака молочной железы. М.: МИА. 2008. 288с.

20. Park I. H., Han H. S., Lee H. et al. Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer // Ann Oncol. 2012. — Vol. 23 (9). — P.2283-2289.

21. Das M, Shehata F, Son WY et al. Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy // Hum Reprod. — 2012. — Vol. 27 (8). — P.2509-2514.

22. Ruddy KJ, Gelber S, Ginsburg ES. et al. Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors: a comparison to age- and gravidity-matched controls // Menopause. — 2011. — Vol. 18 (1). P.105-108.

23. Aft R. Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid // Int J Womens Health. — 2012. — Vol. 4. — P.569-576.

24. Hadji P, Gnant M, Body J. J. et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? // Cancer Treat Rev. — 2012. — Vol. 38 (6). — P.798-806.

25. Kintzel PE, Chase SL, Schultz LM, O’Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer // Pharmacotherapy. — 2008. — Vol. 28 (12). — P.1511-1522.

26. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer // Cancer. — 2009. — Vol. 115 (11). — P.2388-2399.

27. Nobes J. P., Langley S. E., Klopper T. et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy // BJU Int. — 2012. — Vol.109 (10). — P.1495-1502.

28. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects // BJU Int. — 2013. — Vol. 111 (4). — P.543-548.

29. Берштейн Л. М., Цырлина Е. В., Воробьев А. В. и др. Сочетание полной и неполной андрогенной блокады с метформином в лечении больных раком предстательной железы. Тр. 16-го Росс. онкол. конгресса // Злокачественные опухоли, 2012. — Т.2 (2) — с.153.

30. Lodish MB. Clinical review: kinase inhibitors: adverse effects related to the endocrine system // J. Clin. Endocrinol. Metab. — 2013. — Vol.98 (4). — P.1333-1142.

31. Sivendran S., Agarwal N., Gartrell B. et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy // Cancer Treat Rev. 2013 [Epub ahead of print]

32. Paplomata E, Zelnak A, O’Regan R. Everolimus: side effect profile and management of toxicities in breast cancer // Breast Cancer Res Treat. –2013. — Vol. 140 (3). — P.453-462.

33. Cummins M., Pavlakis N. The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events // Ther. Adv. Med. Oncol. — 2013. — Vol. 5 (5). — P.286-300.

34. Mortimer JE, Flatt SW, Parker BA. et al. Tamoxifen, hot flashes and recurrence in breast cancer // Breast Cancer Res Treat. — 2008. — Vol. 108 (3). — P.421-426.

35. Fontein D. B., Houtsma D., Hille E. T. et al. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausalbreast cancer patients // Ann Oncol. 2012. — Vol. 23 (12). — P.3091-3097.

36. Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D. et al. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study // Breast Cancer Res Treat. — 2013. — Vol. 140 (2). — P.385-395.

37. Henry NL, Skaar TC, Dantzer J. et al. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer // Breast Cancer Res Treat. — 2013. — Vol.138 (3). — P.807-816.